India, Nov. 12 -- Divya Jain, senior dietician at CK Birla Hospitals, Jaipur, shared six ways to maintain balanced eating habits after festive celebrations, according to an interaction with HT Lifesty... Read More
Singapore, Nov. 12 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Randomized, Placebo-Controlled, Single- and Multiple-Ascending Dose Escalation Study to... Read More
Singapore, Nov. 12 -- The Health Sciences Authority received information related to the study titled 'A Phase II, Open-label Platform Study of Osimertinib in Combination with Anti-cancer Agents in Par... Read More
Singapore, Nov. 12 -- The Health Sciences Authority received information related to the study titled 'A Phase 2, Randomized, Open-Label Dose Optimization and Phase 3, Randomized, Double-Blind, Placebo... Read More
Singapore, Nov. 12 -- The Health Sciences Authority received information related to the study titled 'A Phase 1 Open-Label Study to Determine the Effect of Injection Site on the Relative Bioavailabili... Read More
Singapore, Nov. 12 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety ... Read More
Singapore, Nov. 12 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety ... Read More
Singapore, Nov. 12 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Randomized, Placebo-Controlled, Single and Multiple Ascending Dose-Escalation Study to ... Read More
Singapore, Nov. 12 -- The Health Sciences Authority received information related to the study titled 'A Phase 2 Platform Basket Study Evaluating Advanced Therapies in Subjects with Moderately to Sever... Read More
Singapore, Nov. 12 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Open-Label Study of Rinzimetostat (ORIC-944) in Combination with Darolutami... Read More